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ProgressionTumor recurrence and metastasis remain the major obstacles for the successful treatment of patients diagnosed
with gastric cancer. In recent years, long non-coding RNAs (lncRNAs) have been considered as key regulators of
tumor behavior. In this study, we investigated the expression and biological role of a newly-identiﬁed cancer-
related lncRNA, WT1-AS. We found that WT1-AS expression was signiﬁcantly down-regulated in tumor tissues
compared to matched adjacent non-tumor tissues. The WT1-AS expression level was also associated with
tumor size and the clinicopathological stage. Cell proliferation, migration, and invasion were inhibited, and the
proportion ofG0/G1 cells increasedwhenWT1-ASwas ectopically-expressed in gastric cancer cells. Furthermore,
ectopic expression of WT1-AS was demonstrated to inhibit tumor growth and metastasis in vivo. Finally, we
found that WT1-AS overexpression could decrease ERK protein phosphorylation. Our study indicates that
WT1-AS is signiﬁcantly down-regulated in gastric cancers and may be correlated with tumor progression.
© 2015 Published by Elsevier B.V.1. Background
Gastric cancer (GC) is one of the most frequently diagnosed cancers
worldwide [1]. Despite survival advantages achieved by using synthetic
treatment, post-operation relapse and metastasis of the tumor remain
themain challenges for clinical care and curative procedures [2]. There-
fore, elucidating themechanismof tumormetastasis has signiﬁcance for
cancer treatment. Recently, long non-coding RNAs (lncRNAs) have been
demonstrated to be involved in tumor metastasis, which has drawn ex-
tensive attention from the scientiﬁc and medical community [3–5].
LncRNAs represent a type of non-coding RNA longer than 200 nucle-
otides (nt), which lack a functional open reading frame [6]. Accumulat-
ing evidence suggests that lncRNAs are key regulatory molecules that
are involved in almost every level of biological processes, including epi-
genetic, transcriptional, and posttranscriptional regulatorymechanismsC, gastric cancer; PRC2, Poly
of Gastric Neoplasms, Shanghai
Ruijin Hospital, Shanghai Jiao
bg@126.com (B. Zhang),
Jiang), zp1377@easthospital.cn
. Yan), zzg1954@hotmail.com[7–9]. LncRNAs are highly diverse and may function as a regulator of
mRNA processing, a reservoir of small ncRNAs, and as a scaffold for
lncRNA–mRNA/miRNA interactions [10–12]. During the past few de-
cades, multiple lncRNAs have been identiﬁed and characterized, such
as HOTAIR, H19, and Xist [13–15]. HOTAIR may serve as scaffold to
bind histone modiﬁers, Polycomb Repressive Complex 2 (PRC2), and
the LSD1 complex, thereby specifying the pattern of histone modiﬁca-
tions and regulating gene expression [13]. Xist is a spliced and
polyadenylated lncRNA, which helps to initiate X chromosome inactiva-
tion by binding and recruiting PRC2 [16]. Importantly, the dysfunction
of some lncRNA molecules has been correlated to a variety of cancers,
while portions of thesemolecules have been considered as potential di-
agnostic cancer biomarkers [17–19]. For example, HOTAIR expression
levels are elevated in multiple types of tumor cells and have been asso-
ciated with poor survival outcomes and high tumor recurrence rates
[20–21]. Knockdown of HOTAIR inhibits cell proliferation and decreases
cell invasiveness [20,22]. Previous reports have also shown thatH19 can
upregulate ISM1 expression and processing of miR-675 to regulate cell
proliferation and invasion in gastric cancer [23].
Similarly, more lncRNAs are being identiﬁed and many await func-
tional validation in the context of gastric cancer. WT1-AS is one of the
antisense transcripts of the Wilm's tumor gene, which encodes a zinc
ﬁnger transcription domain with both tumor suppressor and oncogenic
activities [24]. Furthermore, WT1-AS was one of a group of notable
lncRNAs identiﬁed in our previous gene expression proﬁle of gastric
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serval cancers, including ovarian clear cell adenocarcinoma [24,25]. The
WT1-AS promoter has been shown to be signiﬁcantly methylated in
ovarian clear cell adenocarcinoma compared to serous adenocarcinoma,
which can lead to the down-regulation of WT1-AS, relating to a poorer
prognosis (versus serous adenocarcinoma) [25]. However, the precise
role of WT1-AS in cancer remains unclear.
To investigate the function ofWT1-AS in gastric cancer, we explored
the WT1-AS expression level in gastric cancer tissues via quantitative
RT-PCR and investigated its role in cell proliferation, migration, and in-
vasion in vitro and vivo by ectopically overexpressingWT1-AS in gastric
cancer cells.
2. Methods
2.1. Tissues
Ninety one gastric cancer samples were obtained from patients who
had underwent surgery at Ruijin hospital, Shanghai, China between
2011 and 2013. All the samples were diagnosed by pathological exami-
nation. No radiotherapy or chemotherapy was conducted in these pa-
tients before operation. All samples were immediately frozen in liquid
nitrogen and stored at−80 °C. Informed consents were obtained fromFig. 1.WT1-AS expression in gastric cancer tissues and cell lines. A,WT1-AS expression was sig
shown as−ΔΔCt normalized to GAPDH. B, WT1-AS expression was shown as 2−ΔCt (n = 91, *
normal gastric cell line GES-1. Data are from three independent experiments.all patients. The study was approved by the Human Research Ethics
Committee of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong
University (Permit number: HREC08–028).
2.2. Cell lines and culture
Gastric cancer cell lines SGC7901, BGC823, MKN45, MKN28, NCI-
N87, AGS, HS-746T and an immortalized normal gastric epithelial cell
line GES-1 were preserved in the institute. Cells were cultured in
RPMI-1640medium containing 10% fetal calf serumwith 100U/ml pen-
icillin and 100 μg/ml streptomycin (GIBCO BRL, Gaithersburgh, MD,
USA). Cells were maintained at 37 °C in a humidiﬁed atmosphere of
5% CO2.
2.3. RNA extraction and qRT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer's instructions. cDNA was ob-
tained using a reverse transcription kit (Promega, WI, USA). qPCR was
performed using the SYBR Select Master Mix (Applied Biosystems,
Carlsbad, CA, USA) on ABI 7900 system. Relative expression was calcu-
latedwith GAPDH using the 2−ΔCt and−ΔΔCtmethod. The primers se-
quences were as follows: WT1-AS : 5′-GCCTCTCTGTCCTCTTCTTTGT-3′niﬁcantly down-regulated in tumor tissues from gastric cancers (qRT-PCR, n= 91). Data is
*P b 0.01). C, WT1-AS expression in human gastric cancer cell lines and the immortalized
Table 1
Correlationship betweenWT1-AS expression level and clinicopathologic characteristics in
gastric cancer tissues.
Clinicopathologic parameters WT1-AS expression P
High (n = 31) Low (n = 60)
Age (years)
≤60 18 39 0.517
N60 13 21
Gender
Male 14 34 0.297
Female 17 26
Tumor size (cm)
≤5 20 24 0.027
N5 11 36
Lauren classiﬁcation
Intestinal 21 45 0.462
Diffuse 10 15
Differentiation
Well, moderately 19 43 0.314
Poorly, undifferentiated 12 17
Local invasion
T1, T2 22 29 0.039
T3, T4 9 31
Lymph node metastasis
No 7 12 0.774
Yes 24 48
TNM stage
I, II 23 31 0.038
III, IV 8 29
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TTGGCATCGTTGAGGGTCT-3′(forward), 5′-CAGTGGGAACACGGAAAGC-
3′ (reverse).
2.4. Plasmid and lentivirus construct
To generate a WT1-AS expression vector, the entire sequence of
WT1-AS of human WT1-AS (NR_023920.1) was synthesized and
subcloned into the pL/IRES/GFP plasmid (Novobio, Shanghai, China)
for lentivirus production.
2.5. Cell proliferation assay
Cell proliferation assay was performed with Cell Counting Kit-8
(CCK-8; Dojindo, Kumamoto, Japan). Cells were cultured in a 96-well
plate at a concentration of 1 × 104 cells/ml; OD450 was measured 2 h
after adding CCK-8 every 24 h. For the colony formation assay, 1000
cellswere plated into a 6-well plate andmaintained inmedia containing
10% fetal calf serum. After 2 weeks, cells were ﬁxed with methanol and
stained with 0.1% crystal violet in PBS for 15 min. Visible colonies were
manually counted.
2.6. Cell viablity assay
Cell viablity assay was performed with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetra-zolium bromide (MTT). Cells were cultured in a 96-
well plate at a concentration of 1 × 104 cells/ml. The medium was
addedwith 20 μLMTT (Sigma-Aldrich,MO, USA) every 24 h and incubat-
ed for 4 h at 37 °C. After removing supernatants, formazan crystals were
dissolved with 150 μl of DMSO, and optical densities (OD) were mea-
sured at 490 nm.
2.7. Flow cytometry
For cell cycle analysis, cells were washed with PBS, then harvested
and ﬁxed in 70% ice-cold ethanol at 4 °C overnight. After ﬁxation, cells
were incubatedwith 100 μg/ml RNase at 37 °C for 20min. After staining
with 50 μg/ml propidium iodide in the dark for 30min at room temper-
ature, cell cycle analysis was performed by ﬂuorescence ﬂow cytometry
on a FACScan machine (Beckman Instruments, Fullerton, CA, USA).
2.8. Migration and invasion assay
For the migration assays, cells in 200 μl serum-free medium were
placed into the upper chamber of an insert (Corning, NY, USA) and the
lower chambers were ﬁlled with 600 μl medium containing 10% fetal
calf serum. For the invasion assays, the upper chamber was pre-coated
with diluted Matrigel (BD Biosciences, San Jose, CA, USA). After culture,
the cells on the ﬁlter surfacewere ﬁxed and stainedwith 0.1% Crystal vi-
olet, and photographed with an Olympus BX50 microscope (Olympus
Opticol Co, Japan).
2.9. Wound healing assay
Cells were culture on six-well plates. Once the cells reached 95%
density, the monolayer was wounded with a pipette tip and then incu-
bated in fresh DMEM medium containing 1% fetal calf serum. Wound
closing was observed every 24 h.
2.10. Immunoblotting
Immunoblotting was performed as previously described [26]. ERK,
p-ERK and secondary antibodies were from Cell Signaling Biotechnolo-
gy (MA, USA). GAPDH antibody was from Kangchen Bio-tech Biotech-
nology (Shanghai, China).2.11. In vivo tumorigenesis and metastasis
Four-week-old male BALB/c nude mice (Institute of Zoology,
Chinese Academy of Sciences, Shanghai, China) were housed in speciﬁc
pathogen-free conditions. Cells infected with pL/IRES/GFP or pL/IRES/
GFP-WT1-AS lentivirus were subcutaneously, intraperitoneally and tail
intravenous injected into each mice. Tumor length (L) and width
(W) were measured every 7 days, and tumor volume was calculated
using the equation: volume = (W + L) / 2 × W × L × 0.5236 [27]. At
35 days after injected, mice were sacriﬁced. Tumor growth curves, pul-
monary and peritoneal metastatic nodules were calculated. Tumor
grafts were ﬁxed, embedded in parafﬁn. Sections (5 μm) were stained
with hematoxylin-eosin (HE). All animal experiments were approved
by the Laboratory Animal Ethics Committee of Ruijin Hospital (Permit
Number: 2013062) and performed in accordance with the Guide for
the Care and Use Laboratory Animals of Ruijin Hospital, School of Med-
icine, Shanghai Jiao Tong University.
2.12. Statistical analysis
Statistical analyses were performed using SPSS 19.0 software (SPSS
Inc., Chicago, IL, USA). The relationship between WT1-AS expression
level and clinicopathological parameters were analyzed by the Pearson
χ2 test. Quantitative values were expressed as the means ± SD. Differ-
ences between experimental groups were assessed by the Student's t
test or one-way ANOVA. A two-tailed value of P b 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. WT1-AS expression is down-regulated in human gastric cancer tissues
and cell lines
To understand the signiﬁcance of WT1-AS in gastric cancer, we ﬁrst
evaluatedWT1-AS expression in 91 pairs of gastric cancers and adjacent
non-tumor tissues by qRT-PCR. As shown in Fig. 1A and B, WT1-AS
expression levels were signiﬁcantly down-regulated in tumor tissues
compared to matched adjacent non-tumor tissues. We also found that
WT1-AS expression decreased in gastric cancer cell lines compared to
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we couldn't detect WT1-AS expression in BGC823 and MKN28 cell.
These data indicate that WT1-AS expression is down-regulated in
gastric cancer.
Furthermore, we analyzed the correlation betweenWT1-AS expres-
sion and the clinicopathological parameters present in patients with
gastric cancer. Human gastric cancer tissues were classiﬁed into a
high-WT1-AS group (n = 31) and a low-WT1-AS group (n = 60) ac-
cording to the mean ratio (5.467). As shown in Table 1, the low-WT1-
AS group showed a correlation with larger tumor size, higher TNM
stage, and deeper depth of tumor invasion (P b 0.05). However, there
were no signiﬁcant correlations between WT1-AS expression level and
other clinicopathological characteristics, such as age, gender, and
lymph node metastasis.
Together, these data indicate that abnormalWT1-AS expressionmay
be related to gastric cancer (GC) progression.Fig. 2. Effects ofWT1-ASoverexpression on cell proliferation and cell cycle progression in vitro. A
transfected with pL/IRES/GFP-WT1-AS lentivirus. B, CCK-8 assay was performed to follow the
forming assay. D and E, cell cycle progression was assessed by ﬂow cytometry. Data are repres3.2. Effect of WT1-AS on gastric cancer cell proliferation in vitro
As the WT1-AS expression level is signiﬁcantly down-regulated in
the tumor tissues of gastric cancers, it may function as a tumor suppres-
sor. To this end, we investigated whether overexpression of WT1-AS
could suppress cell proliferation. Gastric cancer cell lines SGC7901 and
HS-746T were transfected with pL/IRES/GFP-WT1-AS or pL/IRES/GFP
lentivirus. Ectopic expression of WT1-AS was then assessed by qPCR
analysis. WT1-AS expression signiﬁcantly increased in pL/IRES/GFP-
WT1-AS-lentivirus transfected SGC7901 (SGC7901/WT1-AS) and HS-
746T (HS-746 T/WT1-AS) cells compared with the controls (Fig. 2A).
CCK-8 and MTT assay also revealed that cell growth was signiﬁcantly
inhibited in WT1-AS overexpressing cells (P b 0.01, Fig. 2B and
P b 0.05, Supplemental Fig. 1 and B). Similarly, the number of colonies
obtained from WT1-AS overexpressing cells was signiﬁcantly lower
than from control cells (230.7 ± 18.9 vs. 364.7 ± 21.4 and 154.7 ±, qPCR analysis of the efﬁcacy ofWT1-AS overexpression. SGC7901 andHS-746T cellswere
proliferation of SGC7901 and HS-746T cells. C, cell proliferation was measured by colony-
ented as the mean ± SD from three independent experiments (*P b 0.05, **P b 0.01).
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overexpression of WT1-AS can suppress GC cell proliferation in vitro.
3.3. WT1-AS is involved in cell cycle progression
To investigate the potential inﬂuences of WT1-AS on the regulation
of cell proliferation, we analyzed cell cycle progression by ﬂow cytome-
try. Our data showed that the percentage of cells in the G1/G0 phase
was signiﬁcantly increased in SGC7901/WT1-AS (from 62.94 ± 1.89%
to 71.61 ± 2.89%, P b 0.05) and in HS-746T/WT1-AS (from 53.25 ±
3.58% to 61.91% ± 3.15%) compared to control cells (Fig. 2D and E).
The percentage of cells in the G2/M and S phases appeared to decrease
in SGC7901/WT1-AS and HS-746 T/WT1-AS cells, although these differ-
enceswere not statistically signiﬁcant (PN 0.05, Fig. 2D and E). These re-
sults suggest that WT1-AS might help to regulate cell cycle progression
in GC cells.
3.4. Overexpression of WT1-AS inhibits cell migration and invasion in vitro
To investigate whether WT1-AS has a functional role in cell migra-
tion and invasion, we performed wound healing, transwell migration,
and invasion assays. As shown in Fig. 3A–D, WT1-AS overexpressionFig. 3. Effects of WT1-AS overexpression on cell migration and invasion in vitro. A and B, tran
SGC7901 and HS-746T cells (100×). C and D, cell migratory abilities were measured by a wo
shown as the mean ± SD of three independent experiments.signiﬁcantly suppressed cell migration, invasion, and wound healing
(P b 0.05). These data show that overexpression of WT1-AS inhibits
cell migration and invasion in vitro.
3.5. ERK protein may be a key downstream mediator of WT1-AS
To explore how WT1-AS may exert its role in GC, we examined the
expression of putative WT1-AS target proteins via immunoblotting.
Our results showed that the expression of phosphorylated ERK protein
(p-ERK) was signiﬁcantly decreased in SGC7901/WT1-AS (density
ratio of p-ERK/ERK: 0.81 ± 0.08 vs. 1.28 ± 0.05 in the control) and
HS-746 T/WT1-AS (0.74 ± 0.38 vs. 1.33 ± 0.03 in the control) (Fig. 4A
and B). However, the mRNA expression of ERK was not altered by
WT1-AS overexpression (data not shown). These ﬁndings suggest that
WT1-AS may inhibit tumor progression by helping to regulate ERK
phosphorylation.
3.6. WT1-AS overexpression can't inhibit GES-1 cell proliferation, cell cycle
progression and invasion
As control, we also investigated whether WT1-AS overexpression
could regulate normal gastric epithelial cell proliferaion, cell cycleswell chamber assay was performed to investigate the migration and invasive abilities of
und healing assay. The wound areas were measured by Image J software. These data are
Fig. 4.WT1-AS overexpression affects ERK protein phosphorylation level. A, im-
munoblotting analysis of p-ERK protein in SGC7901 and HS-746T cells. B, ratio
of phosphorylated ERK to ERK protein in SGC7901 and HS-746T cells (**P b 0.01).
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pL/IRES/GFP-WT1-AS-lentivirus. Cell proliferation, cell cycle population
and cell migration and invasion were analyzed. Results showed that
WT1-AS overexpression couldn't inhibit GES-1 cell proliferation, cell
cycle progression and invasion (P N 0.05, Supplemental Figs. 2 and 3).
Furthermore, WT1-AS overexpression couldn't decrease ERK protein
phosphorylation.3.7. WT1-AS suppresses tumor growth and metastasis in vivo
Finally, we investigated whether WT1-AS could affect tumori-
genesis and metastasis in vivo. HS-746T/WT1-AS, HS-746T/empty
vector, and HS-746T/parental cells were subcutaneously, intra-
peritoneally and tail intravenous inoculated into nude mice, re-
spectively. Five weeks after injection, the tumors formed in HS-
746T/WT1-AS group were signiﬁcantly smaller than those in the
control groups (Fig.5A–D). The average tumor weight was mark-
edly lower in the HS-746T/WT1-AS group than in the control
group (1.14 ± 0.44 g vs. 2.32 ± 0.36 g, P b 0.01, Fig. 5E). Moreover,
the number of pulmonary metastatic nodules was fewer in the
HS-746 T/WT1-AS group than in the control group (2.60 ± 0.89
vs. 6.80 ± 1.32, P b 0.01, Fig. 5F and G). The peritoneal nodules
also decreased in HS-746T/WT1-AS group (3.60 ± 1.14 vs.
8.00 ± 1.22, P b 0.01, Supplemental Fig. 4). These results suggest
that overexpression of WT1-AS inhibits tumor growth and metas-
tasis in vivo.4. Discussion
As molecular research has progressed, lncRNAs have emerged
as one of the diverse classes of cellular transcripts that play impor-
tant roles in stress response, development, alternate splicing, and
chromatin remodeling [10,28,29]. LncRNAs can be classiﬁed into
ﬁve subgroups according to their location and general characteris-
tics: sense, antisense, bidirectional, intronic, and intergenic [30].
Numerous studies have shown that lncRNA molecules are abnor-
mally expressed in prostate, bladder, breast, liver, and ovarian can-
cers, to name a few [20,22,28,31]. Here we identiﬁed a new
antisense lncRNA, WT1-AS, which is implicated in gastric cancer
progression.
WT1-AS is the antisense transcript of WT1, which has been found to
positively regulateWT1protein levels in vivo and play an important role
in the developing kidney [32]. Expression of WT1-AS is correlated with
methylation of the WT1 intron [33]. Evidence suggests that WT1-AS is
present in multiple splice forms and is expressed in parallel with WT1
mRNA in humans and mice [24]. In addition to ovarian cancer, there is
often abnormal splicing of WT1-AS in acute myeloid leukemia, which
may play a role in the development of this malignancy [24]. However,
the prevalence and inﬂuence of WT1-AS expression in gastric cancer is
currently unknown, and the underlying mechanism remains to be
elucidated.
To further conﬁrm our previous study using microarrays, we
assessed WT1-AS expression in gastric cancer tissues and cell lines.
We found that WT1-AS expression was signiﬁcantly down-regulated
in the tumor tissues of gastric cancers. Importantly, reduced expression
of WT1-AS was associated with increased tumor sizes and a more
advanced clinical stage. In addition, ectopic expression of WT1-AS
inhibited cell proliferation, migration, and invasion, while inﬂuencing
the cell cycle progression of gastric cancer in vitro and vivo. Our ﬁndings
suggest that WT1-AS could inhibit tumor progression.
Although WT1-AS expression is correlated with tumor progression,
how it functions in gastric cancer is largely unknown. Unlike miRNA,
the regulatory mechanisms of lncRNA are more complex and diverse
[34]. LncRNAs, such as Xist and HOTAIR, can play guiding roles in cis
and in trans or serve as scaffolds for chromatin modiﬁcation [16,35].
LncRNA, MALAT1, can interact with splicing regulatory proteins, sug-
gesting that lncRNAs may be involved in alternative splicing [10]. Fur-
thermore, studies have shown that lncRNAs can competitively bind to
miRNAs, acting as sponges, which in turn prevents speciﬁc miRNAs
from binding their target mRNAs [36]. Our data suggests that WT1-AS
overexpression might inhibit the proliferation of gastric cancer cells
through G0/G1 arrest. In addition, it is possible that WT1-AS may regu-
late WT1 expression via RNA:RNA interactions, which can become
deregulated by various mechanisms. To explore the underlying mecha-
nism by which WT1-AS contributes to migration and invasion, we ex-
amined the levels of phosphorylated ERK protein in gastric cancer
cells. ERK kinase is an important member of the MAPK family, which
transfers the extracellular signals to the intracellular milieu [37]. Acti-
vated ERK can translocate from the cell membrane into the nucleus to
increase the transcriptional activities of some transcription factors,
such as AP-1 and NF-κB, which in turn regulate gene expression [38].
Abnormal activation of ERK can lead to dysfunctions in cell differentia-
tion and death, which can elicit malignant cell transformations [39,
40]. In our study, we found that WT1-AS overexpression signiﬁcantly
inhibited the phosphorylation of the ERK protein. This indicates that
ERK might be a target protein through which WT1-AS regulates cell
migration and invasion.
In summary, our study has shown thatWT1-AS expression is down-
regulated in gastric cancer tissues and cells. We have shown that WT1-
AS can regulate cancer cell proliferation, cell cycle progression, migra-
tion, and invasion. Furthermore, WT1-AS overexpression signiﬁcantly
inhibits the phosphorylation of ERK. Taken together, our data suggest
thatWT1-ASmight correlatedwith tumor progression in gastric cancer.
Fig. 5. Effects of WT1-AS on tumor growth and metastasis in vivo. A and B, photographs of tumors derived from WT1-AS-overexpressing cells and the control cells. C, H&E stains of
subcutaneous xenograft tumors (200×). D, growth curve of tumors in nude mice. Tumor diameters were measured every 7 days. E, average weight of tumors in nude mice. F, effects
of WT1-AS on pulmonary metastasis. G, H&E stains of pulmonary nodules (40X). Black arrows indicated metastatic tumor nests. H, average numbers of pulmonary nodules in nude
mice (**P b 0.01; n = 5 per group).
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